menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Best Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor Agents

close
Best Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor Agents
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Comments
  • Overview

    The management of metastatic colorectal cancer (mCRC) and metastatic and recurrent loco-regional squamous cell cancer of the head and neck (SCCHN) continues to evolve, not only as new agents reach the clinic but also new understandings of how best to utilize existing agents to optimize clinical outcomes for patients. One of the continuing areas of focus is use of inhibitors of the epidermal growth factor receptor (EGFR) pathway. For both mCRC and metastatic and recurrent loco-regional SCCHN, increasing attention is being placed on second-line approaches as well as first-line application in combination with radiation therapy and/or platinum-based chemotherapy.

Facebook Comments

Recommended
Details
Comments
  • Overview

    The management of metastatic colorectal cancer (mCRC) and metastatic and recurrent loco-regional squamous cell cancer of the head and neck (SCCHN) continues to evolve, not only as new agents reach the clinic but also new understandings of how best to utilize existing agents to optimize clinical outcomes for patients. One of the continuing areas of focus is use of inhibitors of the epidermal growth factor receptor (EGFR) pathway. For both mCRC and metastatic and recurrent loco-regional SCCHN, increasing attention is being placed on second-line approaches as well as first-line application in combination with radiation therapy and/or platinum-based chemotherapy.

Facebook Comments

Programs 6/18/21